Date: Wed, 27 Nov 2024 08:03:41 +0000
Subject: access to documents request - Communication around GLP-1 medications
From: Mathilde de Jeu <[Dirección de correo de la solicitud #15259]>
To: documents requests at EMA <[Dirección de correo del organismo EMA]>

Dear European Medicines Agency,

Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the related to lobbying activities concerning GLP-1 medications:

1. Correspondence:
Emails, letters, or other forms of communication exchanged between representatives of large processed food manufacturers (such as Nestlé, Unilever, and other similar companies), their affiliates, or their lobby organizations (e.g., the European Food Information Council (EUFIC) or similar entities) and officials of the European Medicines Agency (EMA), the European Food Safety Authority (EFSA), or any other EU bodies, regarding GLP-1 medications. This includes discussions on the approval, regulation, or market authorization of GLP-1 drugs (including medications such as Ozempic, Wegovy, Saxenda, and others) and any potential impact or influence these companies may have had on the regulatory processes.
2. Meetings:
Minutes, notes, or summaries of meetings held with representatives of these processed food companies or their lobby organizations, discussing topics such as:
The regulatory process of GLP-1 medications.
The potential market impact of these medications, particularly in the context of weight management and obesity.
Strategies or actions related to influencing EU regulatory decisions on GLP-1 medications, especially those used for weight loss (e.g., Wegovy).
Any discussions on the integration of GLP-1 medications with processed food products or health claims.
3. Documents:
Internal memos, analyses, or reports that refer to lobbying efforts—whether direct or via intermediary organizations—by processed food companies to influence the regulatory assessment of GLP-1 medications. This includes documents discussing the companies' positions on the regulation of GLP-1 drugs, any attempts to delay, alter, or accelerate regulatory decisions, and any concerns raised about how such decisions might affect food consumption behaviors or the broader food and pharmaceutical markets.
4. Consultations and Influence on Regulation:
Any records of consultations between EU bodies and representatives from the processed food industry regarding the regulation of GLP-1 medications, especially regarding their use in weight management. This includes any feedback provided by these companies on proposed regulations, public health guidelines, or any measures that could influence how GLP-1 medications are marketed or perceived by the public, particularly in relation to processed food products.
The timeframe for this request is from 2020 to the present, considering that GLP-1 medications used for weight management and diabetes have gained popularity since that time.

Purpose of the Inquiry:
My inquiry aims to understand the influence and lobbying activities by large processed food companies concerning the regulation and approval of GLP-1 medications. Specifically, I seek to examine whether these companies have sought to influence the regulatory processes surrounding GLP-1 drugs, including how these efforts might affect public health policies, consumer protection, and the broader pharmaceutical and food industries.

If any part of the requested documentation is subject to exemptions under Regulation (EC) No 1049/2001, I kindly ask that you provide detailed reasoning for the redactions or withholdings. I also request that you consider partial disclosure where possible, in the interest of transparency.

Thank you for your time and assistance in processing this request. Please feel free to contact me should you require clarification or additional details regarding this inquiry.

Yours sincerely,

Mathilde de Jeu
The Investigative Desk

-------------------------------------------------------------------

This is a request for access to information under Article 15 of the TFEU and, where applicable, Regulation 1049/2001 which has been sent via the AsktheEU.org website.

Please kindly use this email address for all replies to this request: [Dirección de correo de la solicitud #15259]

If [Dirección de correo del organismo EMA] is the wrong address for information requests to European Medicines Agency, please tell the AsktheEU.org team on email [correo electrónico]

This message and all replies from European Medicines Agency will be published on the AsktheEU.org website. For more information see our dedicated page for EU public officials at https://www.asktheeu.org/en/help/officers

Please note that in some cases publication of requests and responses will be delayed.


-------------------------------------------------------------------